Actemra monotherapy: does it work over the long term?

The fear that tocilizumab (Actemra) may eventually lose its efficacy when used on its own for rheumatoid arthritis is unfounded, say Australian researchers.

In fact, tocilizumab monotherapy shows durable and increasing efficacy over time, they conclude.

In their five-year study of over 130 patients on tocilizumab monotherapy, 40% achieved DAS28 clinical remission after six months, which went up to 65% after five years.